208 related articles for article (PubMed ID: 8722344)
1. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
Demirer T; Buckner CD; Appelbaum FR; Bensinger WI; Sanders J; Lambert K; Clift R; Fefer A; Storb R; Slattery JT
Bone Marrow Transplant; 1996 Apr; 17(4):491-5. PubMed ID: 8722344
[TBL] [Abstract][Full Text] [Related]
2. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
Demirer T; Buckner CD; Appelbaum FR; Lambert K; Bensinger WI; Clift R; Storb R; Slattery JT
Bone Marrow Transplant; 1996 Mar; 17(3):341-6. PubMed ID: 8704684
[TBL] [Abstract][Full Text] [Related]
3. Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.
Petersen FB; Buckner CD; Appelbaum FR; Clift RA; Sanders JE; Bensinger WI; Storb R; Witherspoon RP; Sullivan KM; Bearman SI
Bone Marrow Transplant; 1989 Nov; 4(6):617-23. PubMed ID: 2684307
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality.
McCune JS; Batchelder A; Deeg HJ; Gooley T; Cole S; Phillips B; Schoch HG; McDonald GB
Biol Blood Marrow Transplant; 2007 Jul; 13(7):853-62. PubMed ID: 17580264
[TBL] [Abstract][Full Text] [Related]
5. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation.
Bolinger AM; Zangwill AB; Slattery JT; Risler LJ; Sultan DH; Glidden DV; Norstad D; Cowan MJ
Bone Marrow Transplant; 2001 Dec; 28(11):1013-8. PubMed ID: 11781609
[TBL] [Abstract][Full Text] [Related]
6. Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.
Demirer T; Petersen FB; Bensinger WI; Appelbaum FR; Fefer A; Rowley S; Sanders J; Chauncey T; Storb R; Lilleby K; Buckner CD
Bone Marrow Transplant; 1996 Jul; 18(1):29-34. PubMed ID: 8831992
[TBL] [Abstract][Full Text] [Related]
7. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation of busulfan with pentoxifylline and ciprofloxacin in patients with breast cancer undergoing autologous transplants.
Bensinger WI; Buckner CD; Lilleby K; Holmberg L; Storb R; Slattery JT
Oncology; 2004; 67(5-6):368-75. PubMed ID: 15713992
[TBL] [Abstract][Full Text] [Related]
9. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
[TBL] [Abstract][Full Text] [Related]
11. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N
Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
[TBL] [Abstract][Full Text] [Related]
12. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.
Socié G; Clift RA; Blaise D; Devergie A; Ringden O; Martin PJ; Remberger M; Deeg HJ; Ruutu T; Michallet M; Sullivan KM; Chevret S
Blood; 2001 Dec; 98(13):3569-74. PubMed ID: 11739158
[TBL] [Abstract][Full Text] [Related]
13. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
14. Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle.
Michel G; Socié G; Gebhard F; Bernaudin F; Thuret I; Vannier JP; Demeocq F; Leverger G; Pico JL; Rubie H; Mechinaud F; Reiffers J; Gratecos N; Troussard X; Jouet JP; Simonin G; Gluckman E; Maraninchi D
J Clin Oncol; 1997 Jun; 15(6):2238-46. PubMed ID: 9196136
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM).
Devergie A; Blaise D; Attal M; Tigaud JD; Jouet JP; Vernant JP; Bordigoni P; Ifrah N; Dauriac C; Cahn JY
Blood; 1995 Apr; 85(8):2263-8. PubMed ID: 7718899
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary complications of bone marrow transplantation: a comparison of total body irradiation and cyclophosphamide to busulfan and cyclophosphamide.
Hartsell WF; Czyzewski EA; Ghalie R; Kaizer H
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):69-73. PubMed ID: 7536723
[TBL] [Abstract][Full Text] [Related]
17. Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.
Copelan EA; Avalos BR; Ahn KW; Zhu X; Gale RP; Grunwald MR; Hamadani M; Hamilton BK; Hale GA; Marks DI; Waller EK; Savani BN; Costa LJ; Ramanathan M; Cahn JY; Khoury HJ; Weisdorf DJ; Inamoto Y; Kamble RT; Schouten HC; Wirk B; Litzow MR; Aljurf MD; van Besien KW; Ustun C; Bolwell BJ; Bredeson CN; Fasan O; Ghosh N; Horowitz MM; Arora M; Szer J; Loren AW; Alyea EP; Cortes J; Maziarz RT; Kalaycio ME; Saber W
Biol Blood Marrow Transplant; 2015 Mar; 21(3):552-8. PubMed ID: 25528388
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia.
Uberti JP; Agovi MA; Tarima S; Haagenson M; Gandham S; Anasetti C; Baker KS; Bolwell BJ; Bornhauser M; Chan KW; Copelan E; Davies SM; Finke J; Hale GA; Kollman C; McCarthy PL; Ratanatharathorn V; Ringdén O; Weisdorf DJ; Rizzo JD
Bone Marrow Transplant; 2011 Jan; 46(1):34-43. PubMed ID: 20400989
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of total body irradiation-cyclophosphamide versus busulphan-cyclophosphamide as conditioning regimens for myelogenous leukemia: a meta-analysis].
Xu SX; Tang XH; Chen HQ; Feng B; Xu HQ; Chen XP; Tang XF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1354-60. PubMed ID: 19099643
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
